According to our new research study on “Low Molecular Weight Heparin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type, Packaging, Application, and End User,” the market is expected to grow from US$ 3,658.27 million in 2021 to US$ 5,733.96 million by 2028; it is estimated to grow at a CAGR of 6.6% from 2021 to 2028. The report highlights trends existing in the market, and drivers and hindrances pertaining to the market growth.
The growth of the market is due to advantages of low molecular weight heparin over unfractionated heparin and introduction of LMWH anticoagulants. However, adverse effects of low molecular weight heparin during treatment are expected to restrict the market growth during the forecast period.
The Low Molecular Weight Heparin market majorly consists of the players such as companies such as Aspen Holdings, Changzhou Qianhong Bio-Pharma, Leopharma A/S, Teva Pharmaceutical Industries Ltd., B. Braun Medical, Inc., Pfizer, Inc., Sanofi, Dr. Reddy’s Laboratories Limited, Abbott, and Novartis AG among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Whereas the inorganic strategies such as mergers & acquisitions, partnership, collaborations, were widely seen in the Low Molecular Weight Heparin market.
Get Sample PDF Reportat :-
Anticoagulants prevent clotting of blood and the growth of existing blood clots in blood vessels. In recent years, the development of methods for the prevention, and pharmacological and surgical treatment of thrombosis have improved considerably. The LMWHs are being used in the treatment of antithrombotic diseases for the past two decades. Owing to the structural complexity of anticoagulants and the presence of impurities, their structural characterization requires advanced analytical techniques.
The LMWH exhibits anticoagulant properties such as anti-tumor, anti-inflammatory, and anti-proliferative effects, which are useful in the treatment of pathologies such as nephrotic syndrome and Alzheimer’s disease. The patents of LMWH’s have now expired. However, the market potential for LMWH is growing due to the increasing use in several Western European and emerging countries owing to its uses, such as thromboprophylaxis, venous thromboembolism (VTE), and anticoagulation treatment during pregnancy. As a result, pharmaceutical companies in many countries are focused on producing generic LMWHs.
The spread of the COVID-19 pandemic has emphasized health data sharing and interoperability under the microscope. The infection of novel coronavirus in children is mild compared to adults, and children are assigned a better prognosis. The interruptions in the supply chain and the massive demand for efficient treatments for COVID-19 have put the health research industry in Asia-Pacific in a crucial position.
The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes. In 2021, the multi-vials segment held a larger share of the market, whereas the prefilled syringes segment is expected to register the highest CAGR during 2021–2028.
The global low molecular weight heparin market, based on application, has been segmented into deep vein thrombosis, acute coronary syndrome (ACS), pulmonary embolism, and others. The deep vein thrombosis segment held the largest share of the market in 2021. However, the acute coronary syndrome (ACS) segment is anticipated to register the highest CAGR in the market during the forecast period.
The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospitals segment held the largest share of the market in 2021. However, the ambulatory surgical centers segment is anticipated to register the highest CAGR in the market during the forecast period.
About The Insight Partners
The Insight Partners is a one-stop industry research provider of actionable solutions. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are specialist in industries, such as Healthcare, Media, and Telecommunication.
Our research model is very simple. We believe in client servicing and delivering the best quality to our customers. Through our research content, we are making sure that our customers get value for their money along with better quality data and analysis.
Our research content is majorly focused toward market trends in terms of market sizing, competitive landscaping, company analysis, regional or country analysis, etc. We provide a detailed break-up of segmentation in terms of geography, type, end-users, etc., which helps our clients to gain a deeper analytical understanding of various research topics.
If you have any queries about this report or would like further information, please contact us:
- North America: +1 646 491 9876
- Asia Pacific: +91 20 6727 8686
- Email: [email protected]